Genentech/Novartis Xolair goes before advisory committee
Executive Summary
Asthma treatment Xolair (omalizumab) will go before FDA's Pulmonary-Allergy Drugs Advisory Committee on May 15. Genentech and Novartis are seeking an indication for treatment of moderate-to-severe allergic asthma in adolescents and adults. The firms narrowed the requested indication after FDA deemed the number of patients studied for a younger age group and an allergic rhinitis indication to be insufficient in a July 5, 2001 "complete response" letter. The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at 8 a.m. [To watch a 1webcast of this meeting and other meetings, go to FDAAdvisoryCommittee.com]...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.